Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.56 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15507481 | 0.93 | GLP1R (0.48) | GLP1RTLR2TSHRRECQLNOD1 | |
| SCHEMBL15002878 | 0.90 | GLP1R (0.51) | GLP1RTLR2NOD1GNPATC3AR1 | |
| SCHEMBL15002872 | 0.90 | GLP1R (0.51) | GLP1RGNPATFOLH1 | |
| SCHEMBL29330865 | 0.89 | GLP1R (0.57) | GLP1RTLR2TSHRRECQLNOD1 | |
| SCHEMBL21172251 | 0.86 | GLP1R (0.62) | GLP1RNOD1C3AR1FOLH1 | |
| SCHEMBL24788148 | 0.85 | GLP1R (0.50) | GLP1RTSHRRECQLNOD1 | |
| SCHEMBL16948614 | 0.85 | GLP1R (0.61) | GLP1RNOD1GNPATFOLH1 | |
| SCHEMBL17131138 | 0.84 | GLP1R (0.65) | GLP1RNOD1GNPATC3AR1FOLH1 | |
| SCHEMBL15850010 | 0.84 | GLP1R (0.60) | GLP1RNOD1C3AR1FOLH1 | |
| SCHEMBL15850000 | 0.84 | GLP1R (0.60) | GLP1RNOD1C3AR1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GIPR, IAPP | GLP1R 1/4885TLR2 3724/4885TSHR 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.